Claims
- 31. A physiologically acceptable solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 32. The solution of claim 31 wherein the physiologically acceptable solvent is selected from the group consisting of water, ethanol, polyethylene glycol, dimethyl acetamide, and mixtures thereof.
- 33. The solution of claim 31 wherein the physiologically acceptable solvent is water.
- 34. The solution of claim 31 further comprising a tonicity adjusting agent.
- 35. The solution of claim 31 wherein the concentration of doxorubicin hydrochloride is from 0.1 to 50 mg/ml.
- 36. The solution of claim 31 wherein the concentration of doxorubicin hydrochloride is from 1 to 20 mg/ml.
- 37. The solution of claim 31 wherein the pH of said solution is from about 2.7 to about 3.3.
- 38. The solution of claim 31 wherein said physiologically acceptable solvent is a saline solution.
- 39. The solution of claim 31 wherein said physiologically acceptable solvent is a dextrose solution.
- 40. The solution of claim 31 wherein said physiologically acceptable solvent is sterile water.
- 41. A physiologically acceptable aqueous solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 42. A physiologically acceptable solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, and acetic acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 43. A storage stable physiologically acceptable aqueous solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to about 3.3 with a physiologically acceptable acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml.
- 44. A storage stable physiologically acceptable solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to 3.3 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid and acetic acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml.
- 45. A physiologically acceptable solution of doxorubicin hydrochloride dissolved in a physiologically acceptable aqueous solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml.
- 46. The solution of claim 45 further comprising a tonicity adjusting agent.
- 47. The solution of claim 45 wherein the concentration of doxorubicin hydrochloride is from 0.1 to 50 mg/ml.
- 48. The solution of claim 45 wherein the concentration of doxorubicin hydrochloride is from 1 to 20 mg/ml.
- 49. The solution of claim 45 wherein the pH of said solution is from about 2.7 to about 3.3.
- 50. The solution of claim 45 wherein said physiologically acceptable solvent is a saline solution.
- 51. The solution of claim 45 wherein said physiologically acceptable solvent is a dextrose solution.
- 52. The solution of claim 45 wherein said physiologically acceptable solvent is sterile water.
- 53. A physiologically acceptable solution of doxorubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, and tartaric acid, the concentration of said doxorubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution is in a sealed container and has not been reconstituted from a lyophilizate in said container.
- 54. A physiologically acceptable solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 55. The solution of claim 54 wherein the physiologically acceptable solvent is selected from the group consisting of water, ethanol, polyethylene glycol, dimethyl acetamide, and mixtures thereof.
- 56. The solution of claim 54 wherein the physiologically acceptable solvent is water.
- 57. The solution of claim 54 further comprising a tonicity adjusting agent.
- 58. The solution of claim 54 wherein the concentration of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride is from 0.1 to 50 mg/ml.
- 59. The solution of claim 54 wherein the concentration of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride is from 1 to 20 mg/ml.
- 60. The solution of claim 54 wherein the pH of said solution is from about 2.7 to about 3.3.
- 61. The solution of claim 54 wherein said physiologically acceptable solvent is a saline solution.
- 62. The solution of claim 54 wherein said physiologically acceptable solvent is a dextrose solution.
- 63. The solution of claim 54 wherein said physiologically acceptable solvent is sterile water.
- 64. A physiologically acceptable aqueous solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 65. A physiologically acceptable solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid, and acetic acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution has not been reconstituted from a lyophilizate.
- 66. A storage stable physiologically acceptable aqueous solution of idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to about 3.3 with a physiologically acceptable acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml.
- 67. A storage stable physiologically acceptable solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from about 2.7 to 3.3 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, tartaric acid and acetic acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml.
- 68. A physiologically acceptable solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable aqueous solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, tartaric acid, acetic acid, succinic acid, ascorbic acid, citric acid, and glutamic acid and the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml.
- 69. The solution of claim 68 further comprising a tonicity adjusting agent.
- 70. The solution of claim 68 wherein the concentration of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride is from 0.1 to 50 mg/ml.
- 71. The solution of claim 68 wherein the concentration of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride is from 1 to 20 mg/ml.
- 72. The solution of claim 68 wherein the pH of said solution is from about 2.7 to about 3.3.
- 73. The solution of claim 68 wherein said physiologically acceptable solvent is a saline solution.
- 74. The solution of claim 68 wherein said physiologically acceptable solvent is a dextrose solution.
- 75. The solution of claim 68 wherein said physiologically acceptable solvent is sterile water.
- 76. A physiologically acceptable solution of anthracycline glycoside selected from the group consisting of doxorubicin hydrochloride, epirubicin hydrochloride and idarubicin hydrochloride dissolved in a physiologically acceptable solvent, having a pH adjusted to from 2.5 to 3.5 with a physiologically acceptable acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, and tartaric acid, the concentration of said idarubicin hydrochloride being from 0.1 to 100 mg/ml, wherein said solution is in a sealed container and has not been reconstituted from a lyophilizate in said container.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8519452 |
Aug 1985 |
GB |
|
Parent Case Info
[0001] This is a continuation application of U.S. application Ser. No. 09/945,539, filed Aug. 30, 2001, which is a continuation application of U.S. application Ser. No. 09/149,360, filed Sep. 8, 1998, now U.S. Pat. No. 6,284,738, which is a continuation application of U.S. application Ser. No. 07/827,742, filed Jan. 29, 1992, now U.S. Pat. No. 6,107,285, which is a divisional application of U.S. Ser. No. 07/503,856, filed Apr. 3, 1990, now U.S. Pat. No. 5,124,317, which is a divisional application of U.S. Ser. No. 07/285,999, filed Jul. 27, 1989, now U.S. Pat. No. 4,746,831, which in turn is a continuation application of U.S. Ser. No. 06/878,784, filed Jun. 26, 1986, now abandoned.
Divisions (2)
|
Number |
Date |
Country |
Parent |
07503856 |
Apr 1990 |
US |
Child |
07827742 |
Jan 1992 |
US |
Parent |
07385999 |
Jul 1989 |
US |
Child |
07503856 |
Apr 1990 |
US |
Continuations (4)
|
Number |
Date |
Country |
Parent |
09945539 |
Aug 2001 |
US |
Child |
10454275 |
Jun 2003 |
US |
Parent |
09149360 |
Sep 1998 |
US |
Child |
09945539 |
Aug 2001 |
US |
Parent |
07827742 |
Jan 1992 |
US |
Child |
09149360 |
Sep 1998 |
US |
Parent |
06878784 |
Jun 1986 |
US |
Child |
07385999 |
Jul 1989 |
US |